Fetal hemoglobin in sickle cell anemia

Blood

Volumn 118, Issue 1, 2011, Pages 19-27

  Akinsheye, Idowu ^a   Alsultan, Abdulrahman ^b   Solovieff, Nadia ^c   Ngo, Duyen ^a   Baldwin, Clinton T ^a   Sebastiani, Paola ^c   Chui, David H K ^a   Steinberg, Martin H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA GLOBIN; BCL11A PROTEIN; BETA GLOBIN; BUTYRIC ACID; GAMMA GLOBIN; HBG1 PROTEIN; HBG2 PROTEIN; HEMOGLOBIN F; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; PROTEIN; SAR1A PROTEIN; SODIUM 2,2 DIMETHYLBUTYRATE; UNCLASSIFIED DRUG; VORINOSTAT;

AFRICAN AMERICAN; BETA THALASSEMIA; CHROMOSOME 11P; CHROMOSOME 8Q; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SWITCHING; HAPLOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; PRIORITY JOURNAL; REVIEW; SAUDI ARABIA; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA;

EID: 79960147525     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-325258     Document Type: Review

References (93)

1. Rodgers GP, Steinberg MH. Pharmacologic treatment of sickle cell disease and thalassemia: the augmentation of fetal hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (1st ed). Cambridge, United Kingdom: Cambridge University Press; 2001:1028-1051.
2. Powars D, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4):921-926.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330(23):1639-1644.
4. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, Clinical Management (2nd ed). Cambridge, United Kingdom: Cambridge University Press; 2009.
5. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007;21(1):37-47. (Pubitemid 46110926)
6. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood. 1989; 74(4):1403-1408. (Pubitemid 19227454)
7. Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/ BMP pathway. Br J Haematol. 2006;133(5):570-578.
8. Taylor JG, Nolan VG, Mendelsohn L, et al. Chronic hyperhemolysis in sickle cell anemia: association of vascular complications and mortality with infrequent vasoocclusive pain. PLoS ONE. 2008;3(5):e2095.
9. Jeffers A, Gladwin MT, Kim-Shapiro DB. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Rad Biol Med. 2006;41(10):1557-1565. (Pubitemid 44550083)
10. Pembrey ME,Wood WG,Weatherall DJ, Perrine RP. Fetal haemoglobin production and the sickle gene in the oases of eastern Saudi Arabia. Br J Haematol. 1978;40(3):415-429. (Pubitemid 9027677)
11. El-Hazmi MAF. Heterogeneity and variation of clinical and haematological expression of haemoglobin S in Saudi Arabs. Acta Haematol. 1992; 88(2):67-71. (Pubitemid 23002586)
12. El-Hazmi MAF, Bahakim HM, Warsy AS. DNA polymorphism in the beta-globin gene cluster in Saudi Arabs: relation to severity of sickle cell anaemia. Acta Haematol. 1992;88(2):61-66. (Pubitemid 23002585)
13. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs: a study of 270 subjects. Ann Intern Med. 1978;88(1):1-6. (Pubitemid 8265449)
14. Padmos MA, Roberts GT, Sackey K, et al. Two different forms of homozygous sickle cell disease occur in Saudi Arabia. Br J Haematol. 1991;79(1): 93-98.
15. Adachi K, Kim J, Asakura T, Schwartz E. Characterization of two types of fetal hemoglobin: alpha2 G gamma2 and alpha2 Agamma2. Blood. 1990; 75(10):2070-2075.
16. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood. 1997;89(3):1078-1088.
17. Steinberg MH, Nagel RL. Hemoglobins of the embryo, fetus, and adult. In: Steinberg MH, Forget BG, Higgs DR, Weatherall D, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (2nd ed). Cambridge, United Kingdom: Cambridge University Press; 2009:119-135.
18. Stamatoyannopoulos G, Papayannopoulou T. The switching from hemoglobin F to hemoglobin A formation in man: parallels between the observations in vivo and the findings in erythroid cultures. Prog Clin Biol Res. 1981;55: 665-678.
19. Blau CA, Constantoulakis P, al-Khatti A, et al. Fetal hemoglobin in acute and chronic states of erythroid expansion. Blood. 1993;81(1):227-233.
20. Papayannopoulou T, Vichinsky E, Stamatoyannopoulos G. Fetal Hb production during acute erythroid expansion: I. Observations in patients with transient erythroblastopenia and post-phlebotomy. Br J Haematol. 1980; 44(4):535-546.
21. Stamatoyannopoulos G, Veith R, al-Khatti A, Fritsch EF, Goldwasser E, Papayannopoulou T. On the induction of fetal hemoglobin in the adult: stress erythropoiesis, cell cycle-specific drugs, and recombinant erythropoietin. Prog Clin Biol Res. 1987;251:443-453.
22. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005;33(3):259-271. (Pubitemid 40261307)
23. Stamatoyannopoulos G, Kurnit DM, Papayannopoulou T. Stochastic expression of fetal hemoglobin in adult erythroid cells. Proc Natl Acad Sci U S A. 1981;78(11):7005-7009. (Pubitemid 12216834)
24. Bhanu NV, Trice TA, Lee YT, et al. A sustained and pancellular reversal of gamma-globin gene silencing in adult human erythroid precursor cells. Blood. 2005;105(1):387-393. (Pubitemid 40053109)
25. Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp Hematol. 2008;36(9):1057-1072.
26. Steinberg MH, Nagel RL. Hemoglobin SC disease and hemoglobin C disorders. In: Steinberg MH, Forget BG, Higgs DR,Weatherall DJ, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (2nd ed). Cambridge, United Kingdom: Cambridge University Press; 2009:525-548.
27. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. Vol 4. Oxford, United Kingdom: Blackwell Science; 2001.
28. Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood. 2011;117(15):3945-3953.
29. Nagel RL. Origins and dispersion of the sickle gene. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle Cell Disease: Basic Principles and Clinical Practice. New York, NY: Raven Press; 1994:353-380.
30. Adekile AD. Historical and anthropological correlates of βS haplotypes and α- and β-thalassemia alleles in the Arabian Peninsula. Hemoglobin. 1997;21(3):281-296. (Pubitemid 27193570)
31. Lapoumeroulie C, Dunda O, Ducrocq R, et al. A novel sickle cell mutation of yet another origin in Africa: the Cameroon type. Hum Genet. 1992; 89(3):333-337.
32. Nagel RL, Rao SK, Dunda-Belkhodja O, et al. The hematologic characteristics of sickle cell anemia bearing the Bantu haplotype: the relationship between G gamma and HbF level. Blood. 1987; 69(4):1026-1030. (Pubitemid 17080919)
33. Green NS, Fabry ME, Kaptue-Noche L, Nagel RL. Senegal haplotype is associated with higher HbF than Benin and Cameroon haplotypes in African children with sickle cell anemia. Am J Hematol. 1993; 44(2):145-146. (Pubitemid 23269723)
34. Labie D, Pagnier J, Lapoumeroulie C, et al. Common haplotype dependency of high Gγ-globin gene expression and high HbF levels in β-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci U S A. 1985;82(7):2111-2114. (Pubitemid 15056478)
35. Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa: the Senegal type and the Benin type. N Engl J Med. 1985;312(14):880-884. (Pubitemid 15105672)
36. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010;42(12):1049-1051.
37. Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood. 2000;95(1):342-346. (Pubitemid 30017262)
38. Steinberg MH, Voskaridou E, Kutlar A, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol. 2003; 72(2):121-126. (Pubitemid 36164347)
39. Miller BA, Salameh M, Ahmed M, et al. High fetal hemoglobin production in sickle cell anemia in the eastern province of Saudi Arabia is genetically determined. Blood. 1986;67(5): 1404-1410. (Pubitemid 16080612)
40. Dover GJ, Boyer SH, Pembrey ME. F-cell production in sickle cell anemia: regulation by genes linked to beta-hemoglobin locus. Science. 1981; 211(4489):1441-1444.
41. Gibney GT, Panhuysen CI, So JC, et al. Variation and heritability of Hb F and F cells among beta-thalassemia heterozygotes in Hong Kong. Am J Hematol. 2008;83(6):458-464. (Pubitemid 351742793)
42. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5′ olfactory receptor gene cluster. Blood. 2010;115(9):1815-1822.
43. Sedgewick A, Timofeev N, Sebastiani P, et al. BCL11A (2p16) is a major HbF quantitative trait locus in three different populations. Blood Cells Mol Dis. 2008;41(3):255-258.
44. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A. 2008;105(33): 11869-11874.
45. Close J, Game L, Clark B, Bergounioux J, Gerovassili A, Thein SL. Genome annotation of a 1.5 Mb region of human chromosome 6q23 encompassing a quantitative trait locus for fetal hemoglobin expression in adults. BMC Genomics. 2004;5(1):33.
46. Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108(3):1077-1083. (Pubitemid 44154648)
47. Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15a and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci U S A. 2011;108(4):1519-1524.
48. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A. 2007; 104(27):11346-11351. (Pubitemid 47175143)
49. Farrell JJ, Sherva RM, Luo HY, et al. A 3-bp deletion between transcription factor binding motifs in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression [published online ahead of print March 8, 2011]. Blood. doi:blood-2010-11-317081.
50. Makani J, Menzel S, Nkya S, et al. Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood. 2010;117(4):1390-1392.
51. Creary LE, Ulug P, Menzel S, et al. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One. 2009; 4(1):e4218.
52. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet. 2007;39(10):1197-1199. (Pubitemid 47482679)
53. Uda M, Galanello R, Sanna S, et al. Genomewide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A. 2008;105(5):1620-1625. (Pubitemid 351346564)
54. Thein SL, Menzel S, Lathrop M, et al. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet. 2009;18(R2):R216-R223.
55. Garner C, Silver N, Best S, et al. A quantitative trait locus on chromosome 8q influences the switch from fetal to adult hemoglobin. Blood. 2004;104(7):2184-2186. (Pubitemid 39297877)
56. Garner CP, Tatu T, Best S, et al. Evidence of genetic interaction between the beta-globin complex and chromosome 8q in the expression of fetal hemoglobin. Am J Hum Genet. 2002;70(3):793-799. (Pubitemid 34177935)
57. Garner C, Menzel S, Martin C, et al. Interaction between two quantitative trait loci affects fetal haemoglobin expression. Ann Hum Genet. 2005; 69(6):707-714. (Pubitemid 41556324)
58. Sebastiani P, Wang L, Nolan VG, et al. Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations. Am J Hematol. 2008; 83(3):189-195. (Pubitemid 351303941)
59. Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007;7(6):386-394. (Pubitemid 350187450)
60. Bianchi ME, Beltrame M. Flexing DNA: HMG-box proteins and their partners. Am J Hum Genet. 1998;63(6):1573-1577.
61. Kumkhaek C, Taylor JG, Zhu J, et al. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol. 2008;141(2): 254-259. (Pubitemid 351406217)
62. Tang DC, Zhu J, Liu W, et al. The hydroxyurea-induced small GTP-binding protein SAR modulates gamma-globin gene expression in human erythroid cells. Blood. 2005;106(9): 3256-3263. (Pubitemid 41565927)
63. Chang YC, Smith KD, Moore RD, et al. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, β-globin haplotypes, α-globin gene number, gender, and age. Blood. 1995;85(4):1111-1117.
64. Chang YPC, Maier-Redelsperger M, Smith KD, et al. The relative importance of the X-linked FCP locus and β-globin haplotypes in determining haemoglobin F levels: a study of SS patients homozygous for βS haplotypes. Br J Haematol. 1997;96(4):806-814. (Pubitemid 27115878)
65. Steinberg MH, Lu ZH, Nagel RL, et al. Hematological effects of atypical and Cameroon betaglobin gene haplotypes in adult sickle cell anemia. Am J Hematol. 1998;59(2):121-126. (Pubitemid 28443238)
66. Mpollo MS, Beaudoin M, Berg PE, et al. BP1 is a negative modulator of definitive erythropoiesis. Nucleic Acids Res. 2006;34(18):5232-5237. (Pubitemid 44742487)
67. Elion J, Berg PE, Lapoumeroulie C, et al. DNA sequence variation in a negative control region 5′ to the beta-globin gene correlates with the phenotypic expression of the beta s mutation. Blood. 1992;79(3):787-792.
68. Galanello R, Melis MA, Podda A, et al. Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome. Blood. 1990;75(8):1747-1749. (Pubitemid 20145771)
69. Kulozik AE, Yarwood N, Jones RW. The Corfu delta beta zero thalassemia: a small deletion acts at a distance to selectively abolish beta globin gene expression. Blood. 1988;71(2):457-462. (Pubitemid 18089537)
70. Acquaye JK, Omer A, Ganeshaguru K, et al. Nonbenign sickle cell anaemia in western Saudi Arabia. Br J Haematol. 1985;60(1):99-108. (Pubitemid 15062989)
71. Annobil SH, Omojola MF, Adzaku FK, et al. Cerebrovascular accidents (strokes) in children with sickle cell disease residing at high and low altitudes of Saudi Arabia. Ann Trop Paediatr. 1990; 10(2):191-198. (Pubitemid 20245573)
72. Al-Jam'a AH, Al-Dabbous IA, Chirala SK, et al. Splenic function in sickle cell anemia patients in Qatif, Saudi Arabia. Am J Hematol. 2000;63(2): 68-73.
73. Alsultan A, Solovieff N, Aleem A, et al. Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern Province have similar HBB haplotypes but higher HbF levels than African Americans [published online ahead of print April 13, 2011]. Am J Hematol. doi:10.1002/ajh.22032.
74. Perrine RP, Brown MJ, Clegg JB, et al. Benign sickle-cell anaemia. Lancet. 1972;2(7788):1163-1167.
75. Miller BA, Salameh M, Ahmed M, et al. Analysis of hemoglobin F production in Saudi Arabian families with sickle cell anemia. Blood. 1987; 70(3):716-720. (Pubitemid 18027403)
76. Miller BA, Olivieri N, Salameh M, et al. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N Engl J Med. 1987;316(5):244-250. (Pubitemid 17051050)
77. Liu LR, Du ZW, Zhao HL, et al. T to C substitution at -175 or -173 of the gamma-globin promoter affects GATA-1 and Oct-1 binding in vitro differently but can independently reproduce the hereditary persistence of fetal hemoglobin phenotype in transgenic mice. J Biol Chem. 2005;280(9):7452-7459.
78. Wood WG. Hereditary persistence of fetal hemoglobin and δβ-thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL, eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management (1st ed). Cambridge, United Kingdom: Cambridge University Press; 2001:356-388.
79. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20): 1317-1322.
80. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005;105(2):545-547. (Pubitemid 40070734)
81. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: results of a 17-year, single center trial (LaSHS). Blood. 2010;115(12):2354-2363.
82. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645-1651. (Pubitemid 37430269)
83. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403-408.
84. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938. (Pubitemid 351860825)
85. Wang WC, Ware RE, Miller CT, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663-1672.
86. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest. 1984;74(2):652-656. (Pubitemid 14054015)
87. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6): 1790-1797. (Pubitemid 29128478)
88. Sutton M, Nassif I, Stamatoyannopoulos G, et al. Absence of cross-resistance to the Hb F stimulating activities of butyrate and hydroxyurea. Blood. 1998;92(suppl 1):694a.
89. Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010;115(12):2483-2490.
90. Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010;107(28):12617-12622.
91. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842.
92. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 2003;102(12):3865-3870. (Pubitemid 37486964)
93. Bauer DE, Orkin SH. Update on fetal hemoglobin gene regulation in hemoglobinopathies. Curr Opin Pediatr. 2011;23(1):1-8.